Independent Market Access and Reimbursement Risk Assessment.

Built by former payers, HTA reviewers, and Industry Experts.

Archives: Reports

MARA Rating Company
February 10, 2026

Mounjaro / tirzepatide for treating type 2 diabetes as of September 2025

MARA Rating Company February 10, 2026

Tirzepatide for managing overweight and obesity as of September 2025

MARA Rating Company February 10, 2026

Vanzacaftor-tezacaftor-deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over as of July 2025

MARA Rating Company February 10, 2026

Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer as of November 2025

MARA Rating Company February 10, 2026

Fasenra / benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis as of September 2025

MARA Rating Company February 10, 2026

Itulazax for treating moderate to severe allergic rhinitis or conjunctivitis caused by tree pollen as of August 2025

MARA Rating Company February 10, 2026

Cabotegravir for preventing HIV-1 in adults and young people as of November 2025

MARA Rating Company February 10, 2026

Cemiplimab / libtayo for untreated advanced non-small-cell lung cancer as of November 2025

MARA Rating Company February 10, 2026

Darolutamide for treating hormone-sensitive metastatic prostate cancer as of November 2025

MARA Rating Company February 10, 2026

Delgocitinib for treating moderate to severe chronic hand eczema as of November 2025

MARA Rating Company February 10, 2026